Fountzilas C, Rosario S, Witkiewicz AK, Withers HG, et al. TP53 mutation is associated with improved disease control in patients with advanced RAS wild-type colorectal adenocarcinoma treated with cetuximab and pembrolizumab. Int J Cancer 2026;158:3300-3311.
PMID: 41793309